Under the terms of the agreement, Oncolytics issued 1,875,121 common shares in its capital to former holders of private company securities in exchange for all of the issued and outstanding securities of private company.
Announcement (March 2, 2009):
Oncolytics has agreed to acquire an inactive private company.
Under the terms of the transaction, Oncolytics would issue its common shares at an exchange ratio calculated based upon an agreed premium to target's net cash per share at closing and using an ascribed price per common share of Oncolytics of $1.69. The transaction is expected to close in April 2009.
Deal Value (US$ Million) 3.36 Deal Type Acquisition Sub-Category 100% Acquisition Deal Status Completed: 2009-04-09
Deal Participants
Target (Company) Undisclosed Company Acquirer (Company) Oncolytics Biotech, Inc.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index